EGFR and lung cancer: Novel EGFRL858R/T790M selective inhibitors XTF-262 and EGFRT790M/C797S selective inhibitors EAI001 were also utilized to synthesis PROTAC 14o and DDC-01-163, respectively, which exhibited anti-proliferative activities in lung cancer cells with corresponding EGFR-mutations [80, 99].